TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01399996

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Yogurt smoothie without probiotic
Description: A daily 8 oz (240 mg) serving will provide 10x\^y5 cfu/ml of the probiotic (Bifidobacterium animalis subsp. lactis BB12).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Yogurt smoothie with probiotic added post fermentation
Description: A daily 8 oz (240 mg) serving will provide 10x\^y5 cfu/ml of the probiotic (Bifidobacterium animalis subsp. lactis BB12).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Yogurt smoothie with probiotic added pre-fermentation
Description: A daily 8 oz (240 mg) serving will provide 10x\^y5 cfu/ml of the probiotic (Bifidobacterium animalis subsp. lactis BB12).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: A capsule containing the probiotic
Description: A capsule taken daily will provide between 10x\^y9 and 10x\^y10 cfu/ml of the probiotic (Bifidobacterium animalis subsp. lactis BB12).
Study: NCT04144816

Intervention type: OTHER
Intervention: Not applicable (no intervention)
Description: Not applicable (no intervention)
Study: NCT01452256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane
Description: 4-6 Vol %

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: TIVA to achieve BIS value of 40-60
Study: NCT02421042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: 5- or 10-mg single oral dose of E7080, depending on their hepatic status \[Mild (10 mg), Moderate (10 mg), and Severe Hepatic Impairment (5 mg) and Normal Hepatic Function (10 mg)\].
Study: NCT03163966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CR6086
Description: oral CR6086 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CR6086
Description: oral CR6086 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CR6086
Description: oral CR6086 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: oral Methotrexate tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: oral Methotrexate tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: oral Methotrexate tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: oral Methotrexate tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: oral CR6086 Placebo capsules
Study: NCT03315260

Intervention type: DRUG
Intervention: Radium-223 dichloride (Xofigo, BAY88-8223)
Description: Ra-223 is a radiopharmaceutical with an indication to treat Castration Resistant Prostate Cancer (approved indication in Japan)
Study: NCT03416179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glasdegib
Description: Daily Glasdegib (100 mg, PO), beginning on Day 1 and is to continue up to 2 years post randomization.~Following consolidation therapy, glasdegib or placebo will be administered daily for up to 2 years after randomization or until they have minimal residual disease (MRD) negative disease, whichever comes first.~Daily Glasdegib (100 mg, PO) or matching placebo will continue throughout Induction(s) and Consolidation therapies regardless of dose modifications/delays in the chemotherapy.
Study: NCT00430508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets and placebo
Description: olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) Tablet 40mg/0mg + 20mg/12.5mg matching placebo tablet once daily for 8 week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets
Description: olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets 40mg/12.5mg + 20mg/12.5mg matching placebo tablet once daily for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olmesartan medoxomil/hydrochlorothiazide tablets
Description: olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets 40mg/25mg + 20mg/12.5mg matching placebo tablet once daily for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olmesartan medoxomil/hydrochlorothiazide tablets
Description: olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets 20mg/12.5mg + 40mg/0mg matching placebo tablet once daily for 8 weeks
Study: NCT03390062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib, also known as YN968D1, is a tyrosine kinase inhibitor that selectively inhibits the vascular endothelial growth factor receptor-2 (VEGFR2, also known as KDR). It is an orally bioavailable, small molecule agent which is thought to inhibit angiogenesis in cancer cells; specifically apatinib inhibits VEGF-mediated endothelial cell migration and proliferation thus blocking new blood vessel formation in tumor tissue.
Study: NCT02260843

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Generic Fitness
Description: Subjects in this group will receive three fitness lessons in a week while each session last for 1 hour for 12 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tai Chi Intervention
Description: Subjects in this group will receive three tai chi lessons in a week while each session last for 1 hour for 12 weeks
Study: NCT01707693

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Physical Activity Intervention
Description: Physical Activity Information given plus Behavioral counseling using motivational interviewing \& follow-up

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information / Attention Comparison
Description: Physical Activity information given \& follow-up, no behavioral counseling
Study: NCT03055975

Intervention type: DIAGNOSTIC_TEST
Intervention: Detection of residual vital bacteria in the root canal space
Description: Detection of residual vital bacteria in the root canal space. No intervention, as it is an observational study. Vital bacteria are looked for in the samples taken from the root canal space.

Intervention type: DIAGNOSTIC_TEST
Intervention: Detection of residual vital bacteria in the root canal space
Description: Detection of residual vital bacteria in the root canal space. No intervention, as it is an observational study. Vital bacteria are looked for in the samples taken from the root canal space.
Study: NCT01777581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milnacipran

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03115151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Bupivacaine (0.0625%) will be combined with fentanyl for postoperative epidural analgesia via a lumbar epidural catheter

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Hydromorphone
Description: Hydromorphone will be given continuous infusion for intravenous patient controlled analgesia (syringe 25 mg/50 mL).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Fentanyl (2 mcg/ml) will be given via epidural route together with bupivacaine.
Study: NCT02190201

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: videolaryngoscope
Description: a kind of videolaryngoscopes, which are widely used in difficult airways.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Direct laryngoscope
Description: A kind of traditional laryngoscopes
Study: NCT02295319

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individual discharge
Description: See previous description in Arms
Study: NCT01375101

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The patient is directed to use placebo capsule two times a day, ,until the one mouth

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quercetin
Description: The patient is directed to digest quercetin hydrate capsule two times a day,until one mouth
Study: NCT02265653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIL 284 BS tablet C

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIL 284 BS tablet D

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BIIL 284 BS WIF tablet
Study: NCT03756675

Intervention type: OTHER
Intervention: haplotype PBSCT
Description: haplotype peripheral blood stem cell transplantation (PBSCT) of GIAC system
Study: NCT00324155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Intravenous solution; intravenous; 10mg/kg; one dose every 3 weeks for 10 weeks then one dose every 12 weeks starting at Week 24, until disease progression, unacceptable toxicity or withdrawal of consent~In Maintenance phase: Only Ipilimumab: 10mg/kg, every 12 weeks will be continued until disease progression

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Intravenous solution; intravenous; 0 mg; one dose every 3 weeks for 10 weeks then one dose every 12 weeks starting at Week 24; until disease progression, unacceptable toxicity or withdrawal of consent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: Intravenous solution; intravenous; 850 mg/m\^2; one dose every 3 weeks for 22 weeks, until disease progression, unacceptable toxicity or withdrawal of consent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dacarbazine
Description: Intravenous solution; intravenous; 850 mg/m\^2; one dose every 3 weeks for 22 weeks, until disease progression, unacceptable toxicity or withdrawal of consent
Study: NCT03913247

Intervention type: OTHER
Intervention: Size Measurement using a measuring tape, a caliper and a metric
Description: Each patient will have the following measure: measure of the span, the tibia, the ulna, the distance between the hill and the knee, the head, the trunk and the leg. The different measures will be done using a measuring tape and with a caliper. Before leaving the intensive care unit, each patients will be measured according to the WHO standard, that is to say strictly lengthened, using a metric for patient younger than 2 and stand up using a stadiometer for patient older than 2.
Study: NCT00825006

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Triple site pacing mode
Description: The experimental Triple site pacing mode includes pacing with Cardiac resynchronization therapy device using two leads; one in the right ventricle (RV) and one in the left ventricle (LV) but stimulates three sites: LV tip, RV tip and RV ring (instead of the usual two sites: LV tip and RV ring.~Patients with evidence of improved LV dyssinchrony parameters during the triple pacing mode (anodal stimulation) will be programmed to anodal stimulation for 3 months.
Study: NCT01532089

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erlotinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erlotinib Hydrochloride
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib Hydrochloride
Description: Given PO

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01031290

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: daily sessions for 5 days

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: daily sessions for 5 days
Study: NCT01976182

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: methotrexate 10mg / m² orally once a week, (at split doses of 5 mg/m2 in the morning and 5 mg/m2 at night), that is to say 2 tablets of 2.5 mg at each take, during 4 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: cyclophosphamide 100 mg orally once daily, that is to say 2 tablets of 50 mg at each take, during 4 months.
Study: NCT06108921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xylitol Powder
Description: The bilateral nasal cavity was irrigated by using a Sanvic SH903 pulsatile irrigator containing 400 ml of xylitol solution once a day for 2 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Salt Powder
Description: The bilateral nasal cavity was irrigated by using a Sanvic SH903 pulsatile irrigator containing 400 ml of normal saline once a day for 2 months.
Study: NCT02852759

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Selective Cold
Description: The volunteers of intervention group will undergo Selective Cold treatment below 10 degree celsius to neck, supraclavicular interscapular regions for 2 hours daily for 8 weeks. The electroacupuncture is conducted by commercially available device. Hyperinsulinemic euglycemic clamp, glucose tolerance test, blood parameter measurements, and PTC-CT scans will be conducted before and after the intervention. The participants will be instructed to maintain their normal behavior and calorie intake.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Description: Electroacupuncture (EA) is an add-on treatment and it is applied when starting the cold treatment at the cold treated region to patients.The device is Huatuo SDZ-II model made by Suzhou Medical Appliance Factory, China.
Study: NCT01568541

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regular toothpastes
Description: One tooth brushing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Children's toothpastes
Description: One tooth brushing
Study: NCT04010305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sublingual film containing BXCL501 (Dexmedetomidine)
Description: Sublingual film containing BXCL501 (Dexmedetomidine) for the treatment of agitation associated with Schizophrenia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sublingual film containing BXCL501 (Dexmedetomidine)
Description: Sublingual film containing BXCL501 (Dexmedetomidine) for the treatment of agitation associated with Schizophrenia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sublingual film containing BXCL501 (Dexmedetomidine)
Description: Sublingual film containing BXCL501 (Dexmedetomidine) for the treatment of agitation associated with Schizophrenia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sublingual film containing BXCL501 (Dexmedetomidine)
Description: Sublingual film containing BXCL501 (Dexmedetomidine) for the treatment of agitation associated with Schizophrenia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo film
Description: Placebo film for BXCL501
Study: NCT04302597

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Staples
Description: Skin closure using surgical stapler.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tissue adhesive
Description: Skin closure using 2-octylcyanoacrylate tissue adhesive.
Study: NCT02153281

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: phenelzine treatment
Description: Subjects will have a PET and MRI scan before and after treatment with phenelzine.
Study: NCT04277585

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telehealth
Description: Early Psychosis Coordinated Specialty Care Services via telehealth.
Study: NCT02806167

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical algorithm
Description: Patients presenting with suspected acute CES will be assessed in accordance with the algorithm previously outlined.
Study: NCT03788330

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fresh air system with filtration
Description: Using fresh air ventilation combined with PM2.5 filtration system to reduce the indoor PM2.5 concentration in primarty school classrooms

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Fresh air system with filtration
Description: Using fresh air ventilation combined with PM2.5 filtration system to reduce the indoor PM2.5 concentration in primarty school classrooms
Study: NCT01186406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gliadel
Description: Patients will have 1-8 wafers of Gliadel inserted at the time of surgical resection.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: At a minimum of four weeks, but not greater than eight weeks post-craniotomy, subjects will be treated with standard radiation therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin
Description: Avastin (10 mg/kg) will be given every 14 days, and will begin a minimum of 42 days post-operatively.~Beginning two to three weeks after the last radiation therapy, but not greater than eight weeks, subjects will be treated with Avastin (10mg/m2) every 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temodar
Description: At a minimum of four weeks, but not greater than eight weeks post-craniotomy, subjects will be treated with standard radiation therapy and daily Temodar (75mg/m2) for 6.5 weeks of the radiation. In addition, beginning 2-3 weeks after the last radiation therapy, but not greater than 8 weeks, patients will be treated with 5 day Temodar (200 mg/ m2).
Study: NCT01687933

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: three-dimensional glasses(manufactor Vuzix,wrap 920)
Description: The samples were randomly allocated to use three-dimensional glasses for 30 minutes in order to reliving labor pain.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: usual care
Description: Women in Control group did not use the glasses.
Study: NCT05041465

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clay mask
Description: Clay mask powders- French green, Rhassul and bentonite

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clay mask
Description: Clay mask powders- French green, Rhassul and bentonite

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clay mask
Description: Clay mask powders- French green, Rhassul and bentonite
Study: NCT03804307

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: standard treatment
Description: 3000 cGy in 10 daily fractions

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: short course treatment
Description: 2000 cGy in 4 fractions administered twice a day
Study: NCT03456934

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified infant formula
Description: Test formula with lower protein content than standard formula

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard infant formula
Description: Standard infant formula
Study: NCT00624208

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: droperidol and saline
Description: droperidol 20 mcg.kg-1 and saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ondansetron and saline
Description: ondansetron 0.1 mg.kg-1 and saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: droperidol and ondansetron
Description: droperidol 20 mcg.kg-1 and ondansetron 0.1 mg.kg-1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline and saline
Description: saline and saline
Study: NCT03839641

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High fat meal
Description: 60% fat meal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High fat meal
Description: 60% fat meal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low fat meal
Description: 20% fat meal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low fat meal
Description: 20% fat meal
Study: NCT02222467

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KLOX BioPhotonic System
Description: KLOX BioPhotonic System (Multi-LED Light and KLOX Photo Converter Wound Gel) will be administered until wound closure or for a maximum of 16 weeks, followed by a 8-week follow-up period, in association with Standard Of Care for venous leg ulcers.
Study: NCT01650428

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 5 mg/kg, IV (in the vein) over 30-90 minutes, on day 1 of each 2 weekly cycles. Number of cycles: 1-5 (bevacizumab should not be administered during cycle 6).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 5 mg/kg, IV (in the vein) over 30-90 minutes, on day 1 of each 2 weekly cycles. Number of cycles: 1-5 (bevacizumab should not be administered during cycle 6).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 165 mg/m2 IV (intravenous) over 1 hour on day 1 of two weekly cycle. Number of cycles: 1-6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 165 mg/m2 IV (intravenous) over 1 hour on day 1 of two weekly cycle. Number of cycles: 1-6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 165 mg/m2 IV (intravenous) over 1 hour on day 1 of two weekly cycle. Number of cycles: 1-6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 3200 mg/m2 IV (intravenous), continuous infusion over 48 hours starting on day 1 of two weekly cycle. Number of cycles: 1-6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 3200 mg/m2 IV (intravenous), continuous infusion over 48 hours starting on day 1 of two weekly cycle. Number of cycles: 1-6
Study: NCT02890017

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: postoperative hotel
Description: Outpatient surgery First night stay in a defined patient-hotel Patient come for consultation the next morning of surgery to remove the catheter and/or the compressive bandage. The absence of adverse events is checked, the discharge is confirmed and the evaluation questionnaire is given to the patient.~Postoperative consultation at 1 and 3 months.

Intervention type: OTHER
Group type: OTHER
Intervention: conventional hospitalization
Description: Hospitalization for surgery and first postoperative night stay. Postoperative consultation at 1 and 3 months
Study: NCT03747003

Intervention type: OTHER
Intervention: No intervention is provided
Description: No intervention is provided
Study: NCT00970580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB022 With Paclitaxel and Carboplatin
Description: Escalating doses of BIIB022 with fixed dose and schedule of paclitaxel and carboplatin
Study: NCT00820378

Intervention type: OTHER
Intervention: No special interventioin
Description: Comprehensive transthoracic M-mode, 2-dimensional, and Doppler echocardiographic studies will be performed using commercially available equipment. The aortic dimensions were assessed at end-diastole at the different levels: